Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Codabakalner - Spinogenix

Next Previous
Drug Profile

Codabakalner - Spinogenix

Alternative Names: SPG-601

Latest Information Update: 16 Oct 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Spinogenix
  • Class Behavioural disorder therapies; Small molecules
  • Mechanism of Action Large conductance calcium activated potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Fragile X syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Autism spectrum disorder; Fragile X syndrome

Most Recent Events

  • 14 Oct 2026 Phase-II/III clinical trials in Autism-spectrum-disorder (PO) (NCT07439510)
  • 23 Apr 2026 Phase-II/III clinical trials in Fragile X syndrome (PO) (NCT07439510)
  • 09 Apr 2026 Adverse events and efficacy data from a phase-IIa trial in Fragile X syndrome released by Spinogenix

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top